Furthermore, human serum LCN2 is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis16 and reported to correlate to non-alcoholic fatty liver disease (NAFLD)17, ASH disease severity, and the model for end-stage liver disease (MELD) score18. This evidence concerns the gene LCN2 and metabolic dysfunction-associated steatotic liver disease.